Praxis Precision Medicines, Inc.
- PRAX
- NASDAQ
- Biotechnology
- CNS Therapies
- Clinical-Stage Biopharma
$261.32
Today +8.09%Quote Oct 19, 2026, 07:40 PM UTC
−22.13%over the last month
Max drawdown −23.0%From 1-month high −22.1%3 months −20.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
168
Market value
$7.30B
Quote Oct 19
Floor
$246.20
5.8% below price
Resistance
$272.66
4.3% above price
Price vs analyst targets
18 analysts
Lowest target
$162.00Highest target
$1201.00
$162.00Highest target
$1201.00
- Price $261.32
- Average target $611.69
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 134% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PRAXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free